Apyx Medical Corporation, a leader in surgical aesthetics, reported preliminary revenue results for Q4 and full year 2025.
Total revenue is expected to be around $19.0 to $19.2 million for Q4, representing a 34% increase year-over-year.
Surgical Aesthetics revenue surged approximately 38% in Q4, with a 51% increase in the U.S. post the AYON launch.
Strong Performance in Surgical Aesthetics
Surgical Aesthetics revenue increased by 38% in Q4, driven by the success of the AYON launch.
Revenue Growth
Total revenue expected to be in the range of $52.7 to $52.9 million for full year 2025, showcasing a 10% increase year-over-year.
Product Launch Impact
The commercial launch of AYON contributed significantly, with a 51% increase in U.S. Surgical Aesthetics revenue.
- The strong revenue growth in Q4 and full year 2025 reflects Apyx's successful market positioning and product offerings.
- The launch of AYON and Renuvion has positioned Apyx Medical to leverage the growing demand for aesthetic surgical procedures in the U.S.
Apyx Medical Corporation's strong performance in Q4 and full year 2025, driven by the impactful launch of AYON, sets a positive trajectory for future growth and market expansion.